Neoadjuvant, adjuvant and palliative treatment of gastric cancer;Neoadjuvante, adjuvante und palliative Therapie des Magenkarzinoms

Praxis

Volumn 87, Issue 13, 1998, Pages 451-454

  Klein, H O ^a  

^a NONE   (Germany)

Author keywords

Cytostatic drugs, cytokines; Gastric cancer, locally advanced, metastatic; Immunochemotherapy; Palliative, adjuvant, neoadjuvant treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; MITOMYCIN C; RALTITREXED; TOPOTECAN;

ADJUVANT CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CYTOSTASIS; HUMAN; METASTASIS; PROGNOSIS; QUALITY OF LIFE; REVIEW; STOMACH CANCER; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CYTOKINES; HUMANS; PALLIATIVE CARE; PREOPERATIVE CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 0032565111     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Blot W.J., Devesa S.S., Kneller R. W., et al.: Rising incidence of adenocarcinoma of the oesophagus and gastric cardia. JAMA 265: 1287-1289, 1991.
2. Cancer Chemotherapy and Biological Response Modifiers, editors: Pinedo H.M.,Longo D.L., Chabner B.A., Elsevier Verlag, Amsterdam, Lausanne, New York, Oxford, Shannon, Tokyo, Annual 1-16 (1979-1996.)
3. Caudry M.: Gastric Cancer: Radiotherapy and Approaches to Locally Unresectable or Recurrent Disease. Lippincott Company, Philadelphia, pp 181-187, 1992.
4. Engstrom P.F., Lavin P.T., Douglas HO, et al,: Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275). Cancer 55:1868-1871, 1985.
5. Fink U., Stein H.J., Schumacher C., Wilke H.J.: Neoadjuvant chemotherapy for gastric cancer: update. World J. Surg. 19:509-516, 1995.
6. Gentsch H.H.: Maligne Tumoren des Magens. In: Gall F.P., Hermanek P., Tonak J. (eds): Chirurgische Onkologie. Springer, Berlin Heidelberg New York London Paris Tokyo, pp 347-400, 1986.
7. Grem J.L., Chu E., Boarman D. et al.: Biochemical modulation of fluorouracil with leucovorin and interferon: preclinical and clinical investigations. Semin, Oncol. 19 (Suppl. 3): 36-44, 1992.
8. Gunderson L.L., Sosin H.: Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look). Clinicopathologic correlation and implications for adjuvant therapy Int. J. Radiat. Oncol. Biol. Phys. 8:1-11, 1982.
9. Heberer G., Teichmann R.K., Kramling H.-J., et al.: Results of gastric resection for carcinoma of the stomach: The European experience. World J. Surg. 12:374-381, 1988.
10. Hermans J., Bonenkamp J.J., Boon M.C., et al.: Adjuvant therapy after curative resection for gastric cancer: Meta-analysis of randomized trials. J. Clin. Oncol. 11:1441-1447, 1993.
11. Kelsen D., Atiq O.T., Saltz L., et al.: FAMTX versus etoposide, doxorubicin, and cisplatin: A random assignment trial in gastric cancer. J. Clin. Oncol. 10:541-548, 1992.
12. Kelsen D., Karpeh M., Schwartz G., et al.: Neoadjuvant therapy of high-risk gastric cancer: A phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J. Clin. Oncol, 14:1818-1828, 1996.
13. Klein H.O., Wickramanayake P.D., Dieterle F., et al.:Chemotherapieprotokoll zur Behandlung des metastasierenden Magenkarzinoms. Methotrexat, Adriamycin und 5-Fluorouracil. Dtsch. Med. Wochenschr. 107:1708-1712, 1982.
14. Klein H.O., Wickramanayake P.D., Farrkh G.R.: 5-Fluorouracil (5-FU), Adriamycin (ADM), and Methotrexate (MTX) - A Combination Protocol (FAMTX) for Treatment of Metastasized Stomach Cancer. Proc Am Soc Clin Oncol 84:86, 1986.
15. Klein H.O.: Long-term results with FAMTX (5-fluorouracil, adriamycin, methotrexate) in advanced gastric cancer. Anticancer Res. 9: 1025-1026, 1989.
16. Mahjoubi M., Rougier P., Oliviera J., et al.: Phase II Trial of Combined 5-FU + CDDP in gastric cancer. J Cancer Res Clin Oncol(Suppl, Part 1) 116:677, 1990. (abstr).
17. McNeer G., Vanderherg H., Donn F., et al.: A critical evaluation of subtotal gastrectomy for the cure of cancer of the stomach. Ann. Surg. 134: 1-7, 1951.
18. Meyer H.J., Jähne J., Wilke H., et al.: Surgical Treatment of Gastric Cancer: Retrospective Survey of 1704 Operated Cases With Special Reference to Total Gastrectomy as the Operation of Choice. Sem Surg Oncol 17:356-364, 1991.
19. Moller J.O., Estève J., Moller H. et al.: Cancer in the European Community and its Member States. Eur J Cancer 11/12:1167-1256, 1990.
20. Murad A.M., Santiago F.F., Petroianu A., et al.: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37-41, 1993.
21. Owada S.: A clinical study of immunological status in patients with gastric cancer: with special reference to T cell subsets, interleukin-2 in the lymphocytes of peripheral blood. Nippon Geka Gakkai Zasshi 91:52-61, 1990.
22. Pazdur R., Ajani J.A., Winn R. et al.: A phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma. Cancer 69:878-882, 1992.
23. Popiela T., Zembala M., KuligJ. et al.: Postoperative immunochemotherapy (BCG+5-FU) in advanced gastric cancer. Anticancer Res. 8: 1423-1427, 1988.
24. Preusser P., Wilke H., Achterrath W., et al.: Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J. Clin. Oncol. 7:1310-1317, 1989.
25. Pyrhönen S., Kuitunen T., Nyandoto P., et al.: Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Brit. J. Cancer 71:587-591, 1995.
26. Rougier Ph., Wils J., Wilke H., et al.: Advanced Gastric Cancer: Comparison of FAMTX (5-FU, adriamycin, methotrexate) versus ELF (etoposide, 5-FU, leucovorin) versus FUP (infusional 5-FU + cisplatin). Results from an EORTC trial of the GITCCG and the Arbeitsgemeinschaft für innere Onkologie AIO). Eur. J. Cancer 31 A, suppl 5:116, 1995. Abstr. 546.
27. Smith J.W., Brennan M.F., Botet J.F: Preoperative endoscopic ultrasound can predict the risk of recurrence after operation for gastric carcinoma. J. Clin. Oncol. 11:2380-2385, 1993.
28. Statistisches Bundesamt Wiesbaden. Todesursachen 1988. Kohlhammer Verlag. Stuttgart, 1990.
29. Takao H., Saji S., Sugiyama Y. et al.: Effects of serum immunosuppressive factors on the cytotoxicity of lymphokine-activated killer (LAK) cells induced by recombinant interleukin-2 (R-IL2). Nippon Geka Gakkai Zasshi 89:992-998, 1988.
30. Takeshita M., Ohwada S., Nakamura S. et al.: Studies of immunological parameters in patients with gastric carcinoma - with special reference to analyses with monoclonal antibodies of T-lymphocyte subsets and interleukin-2. Nippon Geka Gakkai Zasshi 88:947-954, 1987.
31. Wanebo H., Kennedy B.J., Chmiel J.: Cancer of the stomach. A patient care study by the American College of Surgeons. Ann. Surg. 218:583-592, 1993.
32. Webb A., Cunningham D., Scarffe J.H., et al.: A randomized trial comparing ECF with FAMTX in advanced oesophago-gastric cancer. Proc. ASCO 15(1996.) Abstr.-Nr. 1462.
33. Wilke H., Preusser P., Fink U., et al.: Preoperative Chemotherapy in Locally Advanced and Nonresectable Gastric Cancer: A Phase II Study With Etoposide, Doxorubicin, and Cisplatin. J Clin Oncol 7:1318-1326 , 1989.
34. Wilke H., Preusser P., Fink U., et al.: High Dose Folinic Acid/Etoposide/5-Fluorouracil in Advanced Gastric Cancer - A Phase II Study in Elderly Patients or Patients With Cardiac Risk. Invest New Drugs 8:65-70, 1990.
35. Wils J., Bleiberg H., Dalesio O., et al. : An EORTC Gastrointestinal Study Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer. J. Clin. Oncol. 4:1799-1803, 1986.
36. Wils J., Klein HO, Wagener D.J., et al.: Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - A step ahead in the treatment of advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J. Clin. Oncol. 9:827-831, 1991.